SUBCUTANEOUS PANNICULITIS-LIKE T-CELL LYMPHOMA
Clinical trials for SUBCUTANEOUS PANNICULITIS-LIKE T-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new SUBCUTANEOUS PANNICULITIS-LIKE T-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for SUBCUTANEOUS PANNICULITIS-LIKE T-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare blood cancers: first human trial launches
Disease control Recruiting nowThis study tests a new drug called DR-01 in adults with rare types of leukemia or lymphoma. The goal is to see if it is safe and can shrink tumors. About 200 people will take part in this early-stage trial.
Matched conditions: SUBCUTANEOUS PANNICULITIS-LIKE T-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Dren Bio • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for rare blood cancer: Two-Drug combo trial launches
Disease control Recruiting nowThis phase 3 trial tests whether adding either belinostat or pralatrexate to standard chemotherapy helps people with newly diagnosed peripheral T-cell lymphoma live longer without their cancer getting worse. About 504 participants will be randomly assigned to one of three treatme…
Matched conditions: SUBCUTANEOUS PANNICULITIS-LIKE T-CELL LYMPHOMA
Phase: PHASE3 • Sponsor: Acrotech Biopharma Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Massive T-Cell lymphoma database aims to unlock new insights
Knowledge-focused Recruiting nowThis study is creating a large database of information and tissue samples from 1,000 people with T-cell lymphoma. Researchers will use this data to learn more about the disease and how to improve patient outcomes. Participants provide medical information and optional blood and na…
Matched conditions: SUBCUTANEOUS PANNICULITIS-LIKE T-CELL LYMPHOMA
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC